Can immunohistochemistry of multidrug-resistant proteins replace the histoculture drug response assay in colorectal adenocarcinomas?

Hepato-Gastroenterology

Volumn 59, Issue 116, 2012, Pages 1075-1078

  Lee, Ju Han ^a   Um, Jun Won ^a   Lee, Ji Hye ^b   Kim, Seo Hee ^a   Lee, Eung Seok ^a   Kim, Young Sik ^a  

^a Korea University   (South Korea)

^b Soonchunhyang University   (South Korea)

Author keywords

Cancer; Chemosensitivity; Colon; Multidrug resistant

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; FLUOROURACIL; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASSAY; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; CHEMOSENSITIVITY; COLORECTAL CARCINOMA; DRUG INHIBITION; FEMALE; HISTOCULTURE DRUG RESPONSE ASSAY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS;

EID: 84861362815     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge09411     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
2. Goyle S, Maraveyas A: Chemotherapy for colorectal cancer. Dig Surg 2005; 22:401-414.
3. Furukawa T, Kubota T, Hoffman RM: Clinical applications of the histoculture drug response assay. Clin Cancer Res 1995; 1:305-311.
4. Vescio RA, Redfern CH, Nelson TJ, Ugoretz S, Stern PH, Hoffman RM: In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc Natl Acad Sci USA 1987; 84:5029-5033.
5. Ohie S, Udagawa Y, Aoki D, Nozawa S: Histoculture drug response assay to monitor chemo-response. Methods Mol Med 2005; 110:79-86.
6. Tanino H, Oura S, Hoffman RM, et al.: Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay. Anticancer Res 2001; 21:4083-4086.
7. Nakada S, Aoki D, Ohie S, et al.: Chemosensitivity testing of ovarian cancer using the histoculture drug response assay: sensitivity to cisplatin and clinical response. Int J Gynecol Cancer 2005; 15:445-452.
8. Singh B, Li R, Xu L, et al.: Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 2002; 24:437-442.
9. Suda S, Akiyama S, Sekiguchi H, Kasai Y, Ito K, Nakao A: Evaluation of the histoculture drug response assay as a sensitivity test for anticancer agents. Surg Today 2002; 32:477-481.
10. Sharom FJ: ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008; 9:105-127.
11. Gillet JP, Efferth T, Remacle J: Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 2007; 1775:237-262.
12. Zorzos HS, Lazaris AC, Korkolopoulou PA, et al.: Multidrug resistance proteins and topoisomerase IIalpha expression in colon cancer: association with metastatic potential. Pathology 2003; 35:315-318.
13. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor and mdr gene expression in colorectal cancer. Cancer 1993; 71:2454-2460.
14. Zöchbauer S, Wallner J, Haider K, Depisch D, Huber H, Pirker R: MDR1 RNA transcripts do not indicate long-term prognosis in colorectal carcinomas. Eur J Cancer 1997; 33:1516-1518.
15. Nanashima A, Yamaguchi H, Matsuo S, et al.: Expression of multidrug resistance protein in metastatic colorectal carcinomas. J Gastroenterol 1999; 34:582-588.
16. Takebayashi Y, Akiyama S, Natsugoe S, et al.: The expression of multidrug resistance protein in human gastrointestinal tract carcinomas. Cancer 1998; 82:661-666.
17. Fillpits M, Suchomel RW, Dekan G, et al.: Expression of the multidrug resistance-associated protein (MRP) gene in colorectal carcinomas. Br J Cancer 1997; 75:208-214.
18. Nakahara T, Sakaeda T, Nakamura T, et al.: Chemosensitivity assessed by collagen gel droplet embedded culture drug sensitivity test, and MDR1, MRP1, and MRP2 mRNA expression in human colorectal adenocarcinomas. Pharm Res 2004; 21:406-412.
19. Pham NA, Morrison A, Schwock J, et al.: Quantitative image analysis of immunohistochemical stains using a CMYK color model. Diagn Pathol 2007; 27:2-8.
20. Hayon T, Dvilansky A, Shpilberg O, Nathan I: Appraisal of the MTT-based assay as a useful tool for predicting drug chemosensitivity in leukemia. Leuk Lymphoma 2003; 44: 1957-1962.
21. Longley DB, Harkin DP, Johnston PG.: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3:330-338.
22. Yamada T, Tanaka N, Yokoi K, et al.: Correlation between clinical pathological factors and activity of 5-FU-metabolizing enzymes in colorectal cancer. J Nippon Med Sch 2008; 75:23-27.
23. Vallbohmer D, Kuramochi H, Shimizu D, et al.: Molecular factors of 5-fluorouracil metabolism in colorectal cancer: analysis of primary tumor and lymph node metastasis. Int J Oncol 2006; 28:527-533.
24. Hinoshita E, Uchiumi T, Taguchi K, et al.: Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin Cancer Res 2000; 6:2401-2407.
25. Diestra JE, Scheffer GL, Catala I, et al.: Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 2002; 198:213-219.
26. Gupta N, Martin PM, Miyauchi S, et al.: Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer. Biochem Biophys Res Commun 2006; 343:571-577.